The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Promising Results for Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Pancreatic Cancer

Tanios Bekaii-Saab, MD
Published Online:3:39 PM, Wed June 14, 2017

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses results of the CanStem111P trial, a phase III study of napabucasin plus nab-paclitaxel with gemcitabine in adult patients with metastatic pancreatic adenocarcinoma, during the 2017 ASCO Annual Meeting.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.